Ritonavir (Synonyms: A84538, ABT538, NSC 693184, RTV) |
| カタログ番号GC17303 |
HIVプロテアーゼ阻害剤
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 155213-67-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Ritonavir, previously known as ABT-538, is a potent inhibitor of human immunodeficiency virus type 1 (HIV-1) protease that exhibits potent in vitro inhibition against HIV-1 strain as well as HIV-2 strain with 50% effective concentration EC50 values of 0.022 μM and 0.16 μM respectively. Ritonavir binds to the HIV-1 protease inactivating its function to cleave the Gag and Gag-Pol polyproteins into the core proteins and viral enzymes, which results in the formation of noninfectious viral particles. X-ray crystallographic analysis reveals a hydrophobic cluster between the isopropyl substituent on the P3 thiazolyl group of ritonavir and the side chains of Pro-81 and Val-82 of HIV-1 protease within the complex of ritonavir/HIV-1 protease.
Reference
[1].Kempf DJ, Marsh KC, Denissen JF, McDonald E, Vasavanonda S, Flentge CA, Green BE, Fino L, Park CH, Kong XP, et al. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2484-8.
[2].Markowitz M, Saag M, Powderly WG, Hurley AM, Hsu A, Valdes JM, Henry D, Sattler F, La Marca A, Leonard JM, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med. 1995 Dec 7;333(23):1534-9.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *